BRCA1 and cancer: Early signal targets involve the hallmark pathways of cancer survival (i.e., HER2, EGFR, mTOR, ALK, BRAF, RAS, CDK4/6, BRCA1, NTRK) with aggressive expansion of several hundred more now in active preclinical and clinical investigation or already registered as approved products [26].